As a semi-synthetic taxane, docetaxel has a high antitumor activity and broad anti-tumor applications. It has a wide range of cytotoxic effects on a variety of solid tumors. Docetaxel not only has a higher response rate in the first-line chemotherapy but also becomes valid in ovarian cancer with relapsed, platinum and paclitaxel resistant.

Chemotherapy of ovarian cancer has made great progress since the 1990s. Paclitaxel and carboplatin become the first-line standard for chemotherapy of ovarian cancer. Although it has better remission rate, but about 50% of patients with ovarian cancer in remission eventually relapse. For relapsed or refractory, the poor efficacy of existing treatment options and poor prognosis. The overall 5-year survival rate of ovarian cancer is only about 30%. Resistance to chemotherapy is still the main factor for a prognosis of ovarian cancer. Therefore, select the next-generation drug with fewer side effects, the better the effect of chemotherapy drugs may bring new life to these patients.

Docetaxel is a cell cycle specific drug, a major role in cell cycle M phase, and its mechanism of action is to enhance the polymerization of tubulin and inhibiting microtubule depolymerization, resulting in the formation of stable non-functional microtubules, thus destroying the tumor cells in mitosis. Long intracellular concentrations than paclitaxel three times and stranded when asked. Clinical pharmacology studies have confirmed the strong anti-tumor activity of taxotere to taxol and paclitaxel, taxol no full pay after resistance.

Although paclitaxel plus platinum chemotherapy had a higher response rate, but most patients will eventually relapse. The purpose of the treatment of recurrent ovarian cancer is to prolong survival time and improve the quality of life. Referred to as second-line chemotherapy for recurrent ovarian cancer patients with chemotherapy. Sensitivity to platinum drugs is the most important factor of the impact of second-line chemotherapy chia seed effect. In clinical practice, is sensitive to platinum-based chemotherapy, mainly based on the decision to the recurrence time from the end of the initial platinum-based chemotherapy or non-platinum treatment intervals. According to the time the end of the initial platinum-based chemotherapy to recurrence of recurrent ovarian cancer is divided into platinum sensitive recurrent cancer (previous platinum-based chemotherapy effective withdrawal six months after relapse), and platinum resistance recurrence of cancer (stop platinum chemotherapy, 6 months relapsed or platinum-based chemotherapy is invalid, while chemotherapy side progress). Many studies have shown that docetaxel not only in the first-line chemotherapy of ovarian cancer have a higher response rate, and has a good response rate in recurrent ovarian cancer patients.

Patients with epithelial ovarian cancer, especially for patients with advanced stage, they have short term survival in first-line chemotherapy. Further improving the efficacy of chemotherapy to extend the advanced and recurrent survival period is an important goal in the comprehensive treatment of ovarian cancer. Docetaxel is a semi-synthetic taxane. The pre-clinical studies confirm that docetaxel anti-tumor activity is stronger than paclitaxel and have no cross-resistance with paclitaxel. It also has a good effect on platinum-resistant and paclitaxel-resistant ovarian cancer. As first-line chemotherapy drug irinotecan treatment of epithelial ovarian cancer, the function that docetaxel combined with carboplatin therapy is the same in combination between paclitaxel card platinum. But its neurotoxicity is significantly lower than that of paclitaxel and carboplatin. Moreover, docetaxel also shows a better response in second-line treatment of ovarian cancer. On aspects of improving survival and patients' quality of life, treatment of epithelial ovarian cancer with docetaxel will have good prospects. Source: http://www.cospcn.com